141 related articles for article (PubMed ID: 35833949)
1. Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.
Fendler WP; Pabst KM; Kessler L; Fragoso Costa P; Ferdinandus J; Weber M; Lippert M; Lueckerath K; Umutlu L; Kostbade K; Mavroeidi IA; Schuler M; Ahrens M; Rischpler C; Bauer S; Herrmann K; Siveke JT; Hamacher R
Clin Cancer Res; 2022 Oct; 28(19):4346-4353. PubMed ID: 35833949
[TBL] [Abstract][Full Text] [Related]
2. Initial Clinical Experience with
Ferdinandus J; Costa PF; Kessler L; Weber M; Hirmas N; Kostbade K; Bauer S; Schuler M; Ahrens M; Schildhaus HU; Rischpler C; Grafe H; Siveke JT; Herrmann K; Fendler WP; Hamacher R
J Nucl Med; 2022 May; 63(5):727-734. PubMed ID: 34385340
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
Fu H; Huang J; Zhao T; Wang H; Chen Y; Xu W; Pang Y; Guo W; Sun L; Wu H; Xu P; Su B; Zhang J; Chen X; Chen H
Clin Cancer Res; 2023 Dec; 29(23):4740-4750. PubMed ID: 37801296
[TBL] [Abstract][Full Text] [Related]
4. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
5. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
6. Outcome and safety of rechallenge [
Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
[TBL] [Abstract][Full Text] [Related]
7. Salvage Radioligand Therapy with Repeated Cycles of
Groener D; Baumgarten J; Haefele S; Happel C; Klimek K; Mader N; Nguyen Ngoc C; Tselis N; Chun FKH; Grünwald F; Sabet A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439172
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
9. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry Estimate and Initial Clinical Experience with
Rathke H; Flechsig P; Mier W; Bronzel M; Mavriopoulou E; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
J Nucl Med; 2019 Jun; 60(6):806-811. PubMed ID: 30389816
[TBL] [Abstract][Full Text] [Related]
11.
Kratochwil C; Flechsig P; Lindner T; Abderrahim L; Altmann A; Mier W; Adeberg S; Rathke H; Röhrich M; Winter H; Plinkert PK; Marme F; Lang M; Kauczor HU; Jäger D; Debus J; Haberkorn U; Giesel FL
J Nucl Med; 2019 Jun; 60(6):801-805. PubMed ID: 30954939
[TBL] [Abstract][Full Text] [Related]
12. Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after
Völter F; Mittlmeier L; Gosewisch A; Brosch-Lenz J; Gildehaus FJ; Zacherl MJ; Beyer L; Stief CG; Holzgreve A; Rübenthaler J; Cyran CC; Böning G; Bartenstein P; Todica A; Ilhan H
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33802417
[TBL] [Abstract][Full Text] [Related]
13. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H
Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172
[TBL] [Abstract][Full Text] [Related]
14.
Kessler L; Ferdinandus J; Hirmas N; Bauer S; Dirksen U; Zarrad F; Nader M; Chodyla M; Milosevic A; Umutlu L; Schuler M; Podleska LE; Schildhaus HU; Fendler WP; Hamacher R
J Nucl Med; 2022 Jan; 63(1):89-95. PubMed ID: 33931468
[TBL] [Abstract][Full Text] [Related]
15. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
16. Impact of
Röhrich M; Naumann P; Giesel FL; Choyke PL; Staudinger F; Wefers A; Liew DP; Kratochwil C; Rathke H; Liermann J; Herfarth K; Jäger D; Debus J; Haberkorn U; Lang M; Koerber SA
J Nucl Med; 2021 Jun; 62(6):779-786. PubMed ID: 33097632
[TBL] [Abstract][Full Text] [Related]
17. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
[TBL] [Abstract][Full Text] [Related]
18. [
Wei Y; Cheng K; Fu Z; Zheng J; Mu Z; Zhao C; Liu X; Wang S; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1671-1681. PubMed ID: 34870727
[TBL] [Abstract][Full Text] [Related]
19. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using
Baum RP; Schuchardt C; Singh A; Chantadisai M; Robiller FC; Zhang J; Mueller D; Eismant A; Almaguel F; Zboralski D; Osterkamp F; Hoehne A; Reineke U; Smerling C; Kulkarni HR
J Nucl Med; 2022 Mar; 63(3):415-423. PubMed ID: 34168013
[TBL] [Abstract][Full Text] [Related]
20. In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2
Prasad V; Huang K; Prasad S; Makowski MR; Czech N; Brenner W
Front Oncol; 2021; 11():578093. PubMed ID: 33816225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
